A 52-year-old man with a 10-year history of major depressive disorder and chronic neuropathic pain (diabetic peripheral neuropathy) presents for medication optimization. His current SSRI is providing inadequate symptom control. Which antidepressant is the drug of choice for this dual indication?

Explanation

## Rationale for Duloxetine as Drug of Choice **Key Point:** Duloxetine is an SNRI with FDA approval for both major depressive disorder AND chronic pain conditions (including diabetic peripheral neuropathy), making it the ideal agent for this dual indication. ### Mechanism of Action Duloxetine is a balanced SNRI that: 1. Inhibits serotonin reuptake → mood elevation, anxiolysis 2. Inhibits norepinephrine reuptake → pain modulation, attention The noradrenergic pathway is particularly important for pain processing in the descending inhibitory pathways of the spinal cord and brainstem. ### FDA Approvals for Duloxetine | Indication | Approval Status | Typical Dose | |---|---|---| | Major Depressive Disorder | ✓ FDA-approved | 40–60 mg/day | | Generalized Anxiety Disorder | ✓ FDA-approved | 60 mg/day | | Diabetic Peripheral Neuropathy | ✓ FDA-approved | 60 mg/day | | Fibromyalgia | ✓ FDA-approved | 60 mg/day | | Chronic Musculoskeletal Pain | ✓ FDA-approved | 60 mg/day | | ADHD | ✗ Not approved | — | **High-Yield:** Duloxetine is the ONLY antidepressant with FDA approval for both depression and neuropathic pain — a unique dual indication that makes it the gold standard for this comorbidity. ### Clinical Pearl The noradrenergic system is crucial for pain modulation. Pure SSRIs (paroxetine, citalopram) lack this component and are ineffective for neuropathic pain. Duloxetine's balanced inhibition of both serotonin and norepinephrine reuptake makes it superior to SSRIs for pain-depression comorbidity [cite:KD Tripathi 8e Ch 12]. ### Comparison with Other Options | Agent | Class | Depression | Neuropathic Pain | Approval | |---|---|---|---|---| | **Duloxetine** | **SNRI** | **✓✓** | **✓✓** | **FDA for both** | | Venlafaxine | SNRI | ✓✓ | ✓ | FDA depression only; off-label for pain | | Paroxetine | SSRI | ✓✓ | ✗ | FDA depression only | | Citalopram | SSRI | ✓✓ | ✗ | FDA depression only | | Imipramine | TCA | ✓✓ | ✓✓ | No FDA approval; older agent | **Mnemonic: DULoxetine = DUaL indication (Depression + pain)** ### Why Not Imipramine (Despite Efficacy)? While imipramine is a TCA with both antidepressant and analgesic properties, it is not first-line because: - Anticholinergic toxicity (dry mouth, urinary retention, constipation) - Cardiac conduction delays and arrhythmia risk - Sedation and weight gain - Requires therapeutic drug monitoring - Narrow margin between therapeutic and toxic doses - Modern SNRIs offer superior safety and tolerability profiles TCAs are now reserved for treatment-resistant cases or specific pain syndromes when SSRIs/SNRIs have failed.